Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
Chen, R Allibone, Suzanne Bartlett, N Brice, P Chen, A Pose, K Rich, L Bonthapally, V Garfin, P Fanale, M
Chen, R
Allibone, Suzanne
Bartlett, N
Brice, P
Chen, A
Pose, K
Rich, L
Bonthapally, V
Garfin, P
Fanale, M
Citations
Altmetric:
Abstract
Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients.
Description
Date
2016
Publisher
Collections
Keywords
Type
Article
Citation
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. 2016, 9:2027-34 Onco Targets Ther